J. Ros , J. Matito , G. Villacampa , R. Comas , A. Garcia , G. Martini , I. Baraibar , N. Saoudi , F. Salvà , Á. Martin , M. Antista , R. Toledo , E. Martinelli , F. Pietrantonio , A. Boccaccino , C. Cremolini , R. Dienstmann , J. Tabernero , A. Vivancos , E. Elez
{"title":"血浆中 BRAF-V600E 等位基因比例作为 BRAF 组合疗法治疗转移性结直肠癌的预后因素 \"的更正:[肿瘤学年鉴 34 (2023) 543-552]。","authors":"J. Ros , J. Matito , G. Villacampa , R. Comas , A. Garcia , G. Martini , I. Baraibar , N. Saoudi , F. Salvà , Á. Martin , M. Antista , R. Toledo , E. Martinelli , F. Pietrantonio , A. Boccaccino , C. Cremolini , R. Dienstmann , J. Tabernero , A. Vivancos , E. Elez","doi":"10.1016/j.annonc.2023.07.010","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"35 10","pages":"Page 922"},"PeriodicalIF":56.7000,"publicationDate":"2024-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0923753423007962/pdfft?md5=bc4ed8a91f804fa67369dbf4a4035573&pid=1-s2.0-S0923753423007962-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Corrigendum to “Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments”\",\"authors\":\"J. Ros , J. Matito , G. Villacampa , R. Comas , A. Garcia , G. Martini , I. Baraibar , N. Saoudi , F. Salvà , Á. Martin , M. Antista , R. Toledo , E. Martinelli , F. Pietrantonio , A. Boccaccino , C. Cremolini , R. Dienstmann , J. Tabernero , A. Vivancos , E. Elez\",\"doi\":\"10.1016/j.annonc.2023.07.010\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":8000,\"journal\":{\"name\":\"Annals of Oncology\",\"volume\":\"35 10\",\"pages\":\"Page 922\"},\"PeriodicalIF\":56.7000,\"publicationDate\":\"2024-08-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S0923753423007962/pdfft?md5=bc4ed8a91f804fa67369dbf4a4035573&pid=1-s2.0-S0923753423007962-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0923753423007962\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0923753423007962","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
Corrigendum to “Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments”
期刊介绍:
Annals of Oncology, the official journal of the European Society for Medical Oncology and the Japanese Society of Medical Oncology, offers rapid and efficient peer-reviewed publications on innovative cancer treatments and translational research in oncology and precision medicine.
The journal primarily focuses on areas such as systemic anticancer therapy, with a specific emphasis on molecular targeted agents and new immune therapies. We also welcome randomized trials, including negative results, as well as top-level guidelines. Additionally, we encourage submissions in emerging fields that are crucial to personalized medicine, such as molecular pathology, bioinformatics, modern statistics, and biotechnologies. Manuscripts related to radiotherapy, surgery, and pediatrics will be considered if they demonstrate a clear interaction with any of the aforementioned fields or if they present groundbreaking findings.
Our international editorial board comprises renowned experts who are leaders in their respective fields. Through Annals of Oncology, we strive to provide the most effective communication on the dynamic and ever-evolving global oncology landscape.